Adipose Tissue-Derived Omentin-1 Function and Regulation
Adipose Tissue-Derived Omentin-1 Function and Regulation
复制标题
DOI：
10.1002/cphy.c160043
复制
发表时间：
2017-07-01
影响因子：
5.8
通讯作者：
Watanabe, Rena
中科院分区：
文献类型：
--
作者：
Watanabe, Takuya;Watanabe-Kominato, Kaho;Watanabe, Rena
网膜素-1（Omentin-1）是一种新发现的脂肪细胞因子，由313个氨基酸组成，在内脏脂肪、间皮细胞、血管细胞、气道杯状细胞、小肠、结肠、卵巢和血浆中均有表达。葡萄糖/胰岛素降低（前）脂肪细胞中网膜素-1的表达水平，并通过成纤维细胞生长因子-21和地塞米松刺激。多项实验研究表明，网膜素-1在维持机体代谢和胰岛素敏感性方面发挥重要作用，并通过AMP活化蛋白激酶/Akt/核因子-κ B/丝裂原活化蛋白激酶（ERK、JNK和p38）信号通路发挥抗炎、抗动脉粥样硬化和心血管保护作用。临床研究表明，循环网膜素-1可用作肥胖、代谢紊乱（包括胰岛素抵抗、糖尿病和代谢综合征）和动脉粥样硬化性心血管疾病的生物标志物。还可以使用循环omentin-1作为骨代谢、炎症性疾病、癌症、睡眠呼吸暂停综合征、先兆子痫和多囊卵巢综合征的生物标志物。omentin-1水平下降通常与这些疾病有关。然而，omentin-1增加以抵消这些疾病发作后的急性期。这些发现表明网膜素-1可能是这些疾病的负性危险因素，并且通过其抗炎和动脉粥样硬化保护作用作为急性相反应物。恢复网膜蛋白-1水平的治疗策略可能对预防或治疗这些疾病有价值。减肥、富含橄榄油的饮食、有氧训练、阿托伐他汀和抗糖尿病药物（二甲双胍、吡格列酮和艾塞那肽）治疗是增加循环网膜素-1水平的有效方法。这篇综述提供了对omentin-1作为这些疾病的生物标志物和治疗靶点的潜在用途的见解。(C)2017美国生理学会。
Omentin-1, also known as intelectin-1, is a recently identified novel adipocytokine of 313 amino acids, which is expressed in visceral (omental and epicardial) fat as well as mesothelial cells, vascular cells, airway goblet cells, small intestine, colon, ovary, and plasma. The level of omentin-1 expression in (pre)adipocytes is decreased by glucose/insulin and stimulated by fibroblast growth factor-21 and dexamethasone. Several lines of experimental evidence have shown that omentin-1 plays crucial roles in the maintenance of body metabolism and insulin sensitivity, and has anti-inflammatory, anti-atherosclerotic, and cardiovascular protective effects via AMP-activated protein kinase/Akt/nuclear factor-kappa B/mitogen-activated protein kinase (ERK, JNK, and p38) signaling. Clinical studies have indicated the usage of circulating omentin-1 as a biomarker of obesity, metabolic disorders including insulin resistance, diabetes, and metabolic syndrome, and atherosclerotic cardiovascular diseases. It is also possible to use circulating omentin-1 as a biomarker of bone metabolism, inflammatory diseases, cancers, sleep apnea syndrome, preeclampsia, and polycystic ovary syndrome. Decreased omentin-1 levels are generally associated with these diseases. However, omentin-1 increases to counteract the acute phase after onset of these diseases. These findings indicate that omentin-1 may be a negative risk factor for these diseases, and also act as an acute-phase reactant by its anti-inflammatory and atheroprotective effects. Therapeutic strategies to restore omentin-1 levels may be valuable for the prevention or treatment of these diseases. Weight loss, olive oil-rich diet, aerobic training, and treatment with atorvastatin and antidiabetic drugs (metformin, pioglitazone, and exenatide) are effective means of increasing circulating omentin-1 levels. This review provides insights into the potential use of omentin-1 as a biomarker and therapeutic target for these diseases. (C) 2017 American Physiological Society.